AI can now turn work that once took days into work that takes hours. That creates an uncomfortable question for marketers: if production time falls sharply, should agency fees fall with it? For pharma agency compensation models, the answer is more complicated than simply dividing a fee by hours worked. New research from the World Federation of Advertisers shows that major brands are already moving away from labor-based payment models. However, pharmaceutical marketing still depends heavily on scientific judgment, regulatory knowledge, strategy, governance, and accountability. Those capabilities do not become less valuable simply because AI makes production faster.
Table of Contents
- Why agency compensation is moving beyond hours
- Why pharma cannot price everything like commodity production
- How output and value-based agency compensation could work in pharma
- Building a smarter compensation model for the AI era
- Conclusion
- Frequently Asked Questions
Why Agency Compensation Is Moving Beyond Hours
Traditionally, agencies have tied fees closely to staffing levels and hours worked. Teams estimate staffing needs, apply hourly rates, and charge clients based partly on the labor required to complete the work. However, AI is making hours a less reliable measure of value.
New World Federation of Advertisers research, developed with Agency Mania Solutions, shows how quickly the market is changing. Labor-based compensation fell from 54% of multinational advertisers in 2011 to just 17% in 2026. Meanwhile, fixed-fee and output-based models rose from 20% to 35%. Labor-plus-performance arrangements also climbed from 9% to 23%.
The research covered 69 multinational companies representing about $147 billion in global marketing spending. Therefore, this is more than a small experiment among early adopters. It reflects a broader reconsideration of what advertisers believe they should actually be buying from agencies.
AI is accelerating that discussion because agencies can now draft, resize, analyze, summarize, version, and optimize work faster. As a result, paying strictly for time can create an unusual incentive. An agency that automates effectively may earn less precisely because it became more efficient.
That is one reason compensation models in pharma are likely to move toward a broader definition of value. Instead of treating time as the main measure of contribution, clients may increasingly look at what was delivered, what expertise was applied, and how effectively the work supported business goals.
Why Pharma Still Pays for Judgment, Not Just Production
Pharmaceutical marketing is not ordinary consumer advertising. A creative asset may be generated quickly, but getting it right still requires experienced people who understand clinical evidence, brand strategy, fair balance, claims, audience needs, and regulatory risk.
For example, AI may generate 20 headline variations in seconds. Yet someone still needs to determine whether those headlines are scientifically supportable, strategically useful, and appropriate for Medical, Legal, and Regulatory review.
That distinction matters. Pharma marketers may need to separate production efficiency from the value of specialized expertise. Faster output does not automatically mean lower-value work.
As Pharma Marketing Network has previously explored, MLR can become part of commercial strategy rather than simply serving as a final approval gate. Likewise, an AI-powered creative workflow may speed asset development, but it can also increase the importance of strong briefs, governance, reusable rules, and expert oversight.
Consequently, an agency that produces an approved campaign in 40 hours instead of 80 hours may actually be delivering more value, not less. The improvement may come from better systems, stronger processes, experienced staff, or well-governed AI tools.
The issue, then, is not whether clients should reward inefficiency. They should not. Instead, the challenge is finding an agency payment model that rewards expertise and useful outcomes without treating hours as the only proof of work.
How Output and Value-Based Agency Compensation Could Work in Pharma
A more modern agency compensation model in pharma could begin with clearly defined outputs. Rather than purchasing a block of staff hours, a brand might agree on fees for a campaign strategy, HCP engagement program, modular content system, launch toolkit, creative platform, media plan, or approved asset package.
This approach gives both sides greater clarity. The client knows what it is buying, while the agency can choose the most efficient combination of people, technology, and AI to deliver it.
However, output pricing should not become a race to the cheapest asset. Two pieces of creative may look similar while requiring very different levels of evidence review, strategic thinking, channel adaptation, and regulatory coordination.
Performance-based compensation introduces another option. According to the WFA findings, performance-linked models are expected to gain further adoption. Yet pharma marketers need to define performance carefully because agencies do not control every factor behind prescriptions, market share, patient starts, or brand growth.
Therefore, metrics should focus on outcomes an agency can reasonably influence. Those could include engagement quality, campaign effectiveness, approved-content utilization, speed to market, media efficiency, or agreed brand measures.
Value-based pricing goes a step further by recognizing the expertise behind the work. A senior strategist who prevents a costly mistake in a one-hour meeting may create more value than dozens of hours of routine production.
This is where pharma agency compensation becomes especially nuanced. The client is not only paying for finished assets. It may also be paying for judgment, risk reduction, scientific credibility, process design, and the ability to navigate a highly regulated environment.
Building a Smarter Compensation Model for the AI Era
For many pharma brands, a hybrid model may make more sense than a single pricing formula. Different types of agency work create value in different ways, so they do not always need to be priced using the same structure.
Routine, repeatable production could move toward fixed or output-based fees. Strategic planning, scientific communications, complex launches, and governance could carry pricing that reflects specialized expertise. In addition, performance incentives could reward measurable improvements where attribution is credible.
Transparency remains essential. The same WFA research found that while 89% of brands believed they received value for money from agencies, only 45% felt they had meaningful transparency into costs. That gap suggests new commercial models will still require clear scopes, assumptions, technology policies, and change-control processes.
Pharma clients should also ask agencies how AI efficiencies are being used. Are they simply reducing staffing, or are they reinvesting time into deeper strategy, better analysis, more testing, stronger quality assurance, and senior expertise?
Similarly, agencies should explain where automation ends and human accountability begins. That is especially important as AI becomes more embedded in pharmaceutical marketing, because regulated brands cannot treat speed as the only measure of progress.
Another important question is whether an agency’s technology advantage should reduce costs, increase output, improve quality, or achieve some combination of the three. Different clients may answer that question differently. Therefore, compensation discussions should focus on expectations before work begins rather than after efficiency gains appear.
Ultimately, a better pharma agency payment model should encourage both parties to work smarter. The goal is not to pay more for fewer hours or demand the same work for less money. Instead, brands and agencies need commercial models that recognize efficiency while protecting the judgment, expertise, and accountability that make the work valuable.
Conclusion
AI is making hours a weaker measure of agency value, and the broader advertising market is already responding. Pharma is likely to follow, although its regulatory and scientific demands make a simple shift away from labor pricing unrealistic.
The stronger approach is to distinguish production from expertise. Fixed fees and output pricing can reward efficiency, while value and performance components can recognize strategic contribution and measurable impact.
In that environment, agency compensation in pharma becomes less about how long the work took and more about what the agency delivered, what expertise it applied, and what business value the partnership created.
Frequently Asked Questions
How does pharma agency compensation work?
Pharma agency compensation refers to the commercial structures pharmaceutical companies use to pay advertising, media, creative, medical communications, and other agency partners. These arrangements may include hourly fees, retainers, fixed project fees, output-based pricing, performance incentives, or hybrid models.
Why is AI changing agency compensation models?
AI can reduce the time required for research, content production, versioning, analysis, and optimization. Therefore, hours worked may no longer accurately reflect the value an agency creates. This is encouraging clients and agencies to consider output, expertise, and business impact alongside time.
Are hourly agency fees disappearing?
Not entirely. Labor-based pricing can still make sense for uncertain or highly variable scopes. However, WFA research shows that multinational advertisers are increasingly adopting fixed-fee, output-based, performance-linked, and value-oriented approaches.
Can pharma use performance-based agency compensation?
Yes, although the metrics need to be carefully selected. Agencies should generally be rewarded against outcomes they can reasonably influence rather than business results controlled by many external factors.
What should pharma marketers ask agencies about AI and fees?
Marketers should ask how AI affects staffing, production costs, quality control, strategic involvement, data governance, and pricing. They should also clarify whether efficiency gains are reducing fees, increasing output, improving quality, or being reinvested in higher-value expertise.
This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.
